Based on the overexpression of NAD(P)H:quinone oxidoreductase-1 (NQO1) and the biotin receptor in cancer cells, compound 35 was designed by the introduction of both biotin and quinone propionic acid into SN38 at C-10 position. This evidence concerns the gene NQO1 and cancer.